Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

August 25, 2011 updated by: Novartis Pharmaceuticals

An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.

This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
No longer available

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Expanded Access

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Saint Leonards, Australia
        • Novartis Investigative Site
  • Austria
      • Graz, Austria
        • Novartis Investigative Site
      • Innsbruck, Austria
        • Novartis Investigative Site
      • Linz, Austria
        • Novartis Investigative Site
      • Wels, Austria
        • Novartis Investigative Site
      • Wien, Austria
        • Novartis Investigative Site
  • Belgium
      • Aalst, Belgium
        • Novartis Investigative Site
      • Antwerpen, Belgium
        • Novartis Investigative Site
      • Arlon, Belgium
        • Novartis Investigative Site
      • Brugge, Belgium
        • Novartis Investigative Site
      • Brussels, Belgium
        • Novartis Investigative Site
      • Bruxelles, Belgium
        • Novartis Investigative Site
      • Edegem, Belgium
        • Novartis Investigative Site
      • Gent, Belgium
        • Novartis Investigative Site
      • Hasselt, Belgium
        • Novartis Investigative Site
      • La Louviere, Belgium
        • Novartis Investigative Site
      • Leuven, Belgium
        • Novartis Investigative Site
      • Liege, Belgium
        • Novartis Investigative Site
      • Roeselare, Belgium
        • Novartis Investigative Site
      • Verviers, Belgium
        • Novartis Investigative Site
      • Yvoir, Belgium
        • Novartis Investigative Site
  • Brazil
      • Belo Horizonte, Brazil
        • Novartis Investigative Site
      • Brasilia-DF, Brazil
        • Novartis Investigative Site
      • Campinas, Brazil
        • Novartis Investigative Site
      • Curitaba, Brazil
        • Novartis Investigative Site
      • Curitiba, Brazil
        • Novartis Investigative Site
      • Porto Alegre-RS, Brazil
        • Novartis Investigative Site
      • Ribeirao Preto, Brazil
        • Novartis Investigative Site
      • Rio de Janeiro, Brazil
        • Novartis Investigative Site
      • Sao Paulo, Brazil
        • Novartis Investigative Site
  • Canada
      • Edmonton, Canada
        • Novartis Investigative Site
      • Halifax, Canada
        • Novartis Investigative Site
      • Hamilton, Canada
        • Novartis Investigative Site
      • Montreal, Canada
        • Novartis Investigative Site
      • Ottawa, Canada
        • Novartis Investigative Site
      • Toronto, Canada
        • Novartis Investigative Site
      • Vancouver, Canada
        • Novartis Investigative Site
  • China
      • Beijing, China
        • Novartis Investigative Site
      • Guangzhou, China
        • Novartis Investigative Site
      • Shanghai, China
        • Novartis Investigative Site
      • Tianjing, China
        • Novartis Investigative Site
  • Czech Republic
      • Brno, Czech Republic
        • Novartis Investigative Site
      • Hradec Kralove, Czech Republic
        • Novartis Investigative Site
      • Olomouc, Czech Republic
        • Novartis Investigative Site
      • Plzen-Lochotin, Czech Republic
        • Novartis Investigative Site
      • Praha 2, Czech Republic
        • Novartis Investigative Site
  • Denmark
      • Copenhagen, Denmark
        • Novartis Investigative Site
      • Vejle, Denmark
        • Novartis Investigative Site
  • France
      • Angers, France
        • Novartis Investigative Site
      • Bordeaux, France
        • Novartis Investigative Site
      • Caen, France
        • Novartis Investigative Site
      • Clermont-Ferrand, France
        • Novartis Investigative Site
      • Creteil, France
        • Novartis Investigative Site
      • Dijon, France
        • Novartis Investigative Site
      • Grenoble, France
        • Novartis Investigative Site
      • Le Chesnay, France
        • Novartis Investigative Site
      • Lille, France
        • Novartis Investigative Site
      • Limoges, France
        • Novartis Investigative Site
      • Lyon, France
        • Novartis Investigative Site
      • Marseille, France
        • Novartis Investigative Site
      • Nantes, France
        • Novartis Investigative Site
      • Nice, France
        • Novartis Investigative Site
      • Paris, France
        • Novartis Investigative Site
      • Poitiers, France
        • Novartis Investigative Site
      • Reims, France
        • Novartis Investigative Site
      • Rennes, France
        • Novartis Investigative Site
      • Rouen, France
        • Novartis Investigative Site
      • Strasbourg, France
        • Novartis Investigative Site
      • Toulouse, France
        • Novartis Investigative Site
      • Vandoeuvre, France
        • Novartis Investigative Site
      • Vandoeuvre les Nancy, France
        • Novartis Investigative Site
  • Germany
      • Aschaffenburg, Germany
        • Novartis Investigative Site
      • Augsburg, Germany
        • Novartis Investigative Site
      • Berlin, Germany
        • Novartis Investigative Site
      • Braunschweig, Germany
        • Novartis Investigative Site
      • Bremen, Germany
        • Novartis Investigative Site
      • Bremerhaven, Germany
        • Novartis Investigative Site
      • Chemnitz, Germany
        • Novartis Investigative Site
      • Dresden, Germany
        • Novartis Investigative Site
      • Essen, Germany
        • Novartis Investigative Site
      • Frankfurt, Germany
        • Novartis Investigative Site
      • Freiburg, Germany
        • Novartis Investigative Site
      • Greifswald, Germany
        • Novartis Investigative Site
      • Hamburg, Germany
        • Novartis Investigative Site
      • Hannover, Germany
        • Novartis Investigative Site
      • Heidelberg, Germany
        • Novartis Investigative Site
      • Kiel, Germany
        • Novartis Investigative Site
      • Koln, Germany
        • Novartis Investigative Site
      • Leipzig, Germany
        • Novartis Investigative Site
      • Mainz, Germany
        • Novartis Investigative Site
      • Mannheim, Germany
        • Novartis Investigative Site
      • Marburg, Germany
        • Novartis Investigative Site
      • Munchen, Germany
        • Novartis Investigative Site
      • Oldenburg, Germany
        • Novartis Investigative Site
      • Osnabruck, Germany
        • Novartis Investigative Site
      • Regensburg, Germany
        • Novartis Investigative Site
      • Stuttgart, Germany
        • Novartis Investigative Site
      • Tubingen, Germany
        • Novartis Investigative Site
      • Ulm, Germany
        • Novartis Investigative Site
      • Weiden, Germany
        • Novartis Investigative Site
      • Wiesbaden, Germany
        • Novartis Investigative Site
  • Greece
      • Athens, Greece
        • Novartis Investigative Site
  • Hong Kong
      • Pokfulam, Hong Kong
        • Novartis Investigative Site
  • Hungary
      • Budapest, Hungary
        • Novartis Investigative Site
  • Ireland
      • Dublin, Ireland
        • Novartis Investigative Site
  • Italy
      • Ancona, Italy
        • Novartis Investigative Site
      • Bari, Italy
        • Novartis Investigative Site
      • Bologna, Italy
        • Novartis Investigative Site
      • Bolzano, Italy
        • Novartis Investigative Site
      • Brescia, Italy
        • Novartis Investigative Site
      • Cagliari, Italy
        • Novartis Investigative Site
      • Campobasso, Italy
        • Novartis Investigative Site
      • Catania, Italy
        • Novartis Investigative Site
      • Catanzaro, Italy
        • Novartis Investigative Site
      • Ferrara, Italy
        • Novartis Investigative Site
      • Firenze, Italy
        • Novartis Investigative Site
      • Genova, Italy
        • Novartis Investigative Site
      • Milano, Italy
        • Novartis Investigative Site
      • Monza, Italy
        • Novartis Investigative Site
      • Napoli, Italy
        • Novartis Investigative Site
      • Novara, Italy
        • Novartis Investigative Site
      • Nuoro, Italy
        • Novartis Investigative Site
      • Orbassano, Italy
        • Novartis Investigative Site
      • Padova, Italy
        • Novartis Investigative Site
      • Palermo, Italy
        • Novartis Investigative Site
      • Pavia, Italy
        • Novartis Investigative Site
      • Perugia, Italy
        • Novartis Investigative Site
      • Pesaro, Italy
        • Novartis Investigative Site
      • Pescara, Italy
        • Novartis Investigative Site
      • Pisa, Italy
        • Novartis Investigative Site
      • Reggio Calabria, Italy
        • Novartis Investigative Site
      • Reggio Emilia, Italy
        • Novartis Investigative Site
      • Rionero in Vulture, Italy
        • Novartis Investigative Site
      • Roma, Italy
        • Novartis Investigative Site
      • Ronciglione, Italy
        • Novartis Investigative Site
      • San Giovanni Rotundo, Italy
        • Novartis Investigative Site
      • Siena, Italy
        • Novartis Investigative Site
      • Tarante, Italy
        • Novartis Investigative Site
      • Torino, Italy
        • Novartis Investigative Site
      • Udine, Italy
        • Novartis Investigative Site
      • Via Pansini, Italy
        • Novartis Investigative Site
  • Korea, Republic of
      • Daegu, Korea, Republic of
        • Novartis Investigative Site
      • Deajeon, Korea, Republic of
        • Novartis Investigative Site
      • Jeollanam-do, Korea, Republic of
        • Novartis Investigative Site
      • Pusan, Korea, Republic of
        • Novartis Investigative Site
      • Seoul, Korea, Republic of
        • Novartis Investigative Site
  • Lebanon
      • Beirut, Lebanon
        • Novartis Investigative Site
  • Malaysia
      • Georgetown, Penang, Malaysia
        • Novartis Investigative Site
      • Kuala Lumpur, Malaysia
        • Novartis Investigative Site
      • Pulau Pinang, Malaysia
        • Novartis Investigative Site
      • Subang Jaya, Selangor, Malaysia
        • Novartis Investigative Site
  • Mexico
      • Mexico D.F., Mexico
        • Novartis Investigative Site
  • Netherlands
      • Amsterdam, Netherlands
        • Novartis Investigative Site
      • Enschede, Netherlands
        • Novartis Investigative Site
      • Leiden, Netherlands
        • Novartis Investigative Site
      • Maastricht, Netherlands
        • Novartis Investigative Site
      • Rotterdam, Netherlands
        • Novartis Investigative Site
  • Norway
      • Oslo, Norway
        • Novartis Investigative Site
  • Poland
      • Gdansk, Poland
        • Novartis Investigative Site
      • Krakow, Poland
        • Novartis Investigative Site
      • Poznan, Poland
        • Novartis Investigative Site
      • Szczecin, Poland
        • Novartis Investigative Site
      • Warszawa, Poland
        • Novartis Investigative Site
  • Russian Federation
      • Chelyabinsk, Russian Federation
        • Novartis Investigative Site
      • Moscow, Russian Federation
        • Novartis Investigative Site
      • Novosibirsk, Russian Federation
        • Novartis Investigative Site
      • Saint-Petersburg, Russian Federation
        • Novartis Investigative Site
      • Samara, Russian Federation
        • Novartis Investigative Site
      • Ufa, Russian Federation
        • Novartis Investigative Site
  • Singapore
      • Singapore, Singapore
        • Novartis Investigative Site
  • Slovakia
      • Bratislava, Slovakia
        • Novartis Investigative Site
      • Kosice, Slovakia
        • Novartis Investigative Site
  • South Africa
      • Cape Town, South Africa
        • Novartis Investigative Site
      • Johannesburg, South Africa
        • Novartis Investigative Site
      • Roodepoort, Gauteng, South Africa
        • Novartis Investigative Site
  • Spain
      • Baracaldo, Pais Vasco, Spain
        • Novartis Investigative Site
      • Barcelona, Cataluna, Spain
        • Novartis Investigative Site
      • Cataluna, Spain
        • Novartis Investigative Site
      • Granada, Andalucia, Spain
        • Novartis Investigative Site
      • Las Palmas de Gran Canaria, Spain
        • Novartis Investigative Site
      • Madrid, Spain
        • Novartis Investigative Site
      • Malaga, Spain
        • Novartis Investigative Site
      • Murcia, Spain
        • Novartis Investigative Site
      • Salamanca, Castilla y Leon, Spain
        • Novartis Investigative Site
      • San Sabastian, Pais Vasco, Spain
        • Novartis Investigative Site
      • Santiago de Compostela, Spain
        • Novartis Investigative Site
      • Valencia, Spain
        • Novartis Investigative Site
      • Zaragoza, Spain
        • Novartis Investigative Site
  • Sweden
      • Goteborg, Sweden
        • Novartis Investigative Site
      • Linkoping, Sweden
        • Novartis Investigative Site
      • Lund, Sweden
        • Novartis Investigative Site
      • Stockholm, Sweden
        • Novartis Investigative Site
      • Uppsala, Sweden
        • Novartis Investigative Site
  • Switzerland
      • Basel, Switzerland
        • Novartis Investigative Site
      • Bern, Switzerland
        • Novartis Investigative Site
      • Lausanne, Switzerland
        • Novartis Investigative Site
      • Zurich, Switzerland
        • Novartis Investigative Site
  • Taiwan
      • Chiayi, Taiwan
        • Novartis Investigative Site
      • Kaohsiung, Taiwan
        • Novartis Investigative Site
      • Taichung, Taiwan
        • Novartis Investigative Site
      • Tainan, Taiwan
        • Novartis Investigative Site
      • Taipei, Taiwan
        • Novartis Investigative Site
  • Thailand
      • Bangkok, Thailand
        • Novartis Investigative Site
  • Turkey
      • Ankara, Turkey
        • Novartis Investigative Site
      • Istanbul, Turkey
        • Novartis Investigative Site
      • Malatya, Turkey
        • Novartis Investigative Site
      • Samsun, Turkey
        • Novartis Investigative Site
  • United Kingdom
      • Cambridge, United Kingdom
        • Novartis Investigative Site
      • Leeds, United Kingdom
        • Novartis Investigative Site
      • Liverpool, United Kingdom
        • Novartis Investigative Site
      • London, United Kingdom
        • Novartis Investigative Site
      • Manchester, United Kingdom
        • Novartis Investigative Site
      • Nottingham, United Kingdom
        • Novartis Investigative Site
  • United States
    • Alabama
      • Mobile, Alabama, United States, 36693
        • University of South Alabama Cancer Research Institute
    • Arizona
      • Tucson, Arizona, United States, 85724
        • Arizona Cancer Center
    • California
      • Duarte, California, United States, 91010
        • City of Hope National Medical Center
      • Lancaster, California, United States, 93534
        • Antelope Valley Cancer Center
      • Palo Alto, California, United States, 94304
        • Stanford University
    • Colorado
      • Aurora, Colorado, United States, 80010
        • University Of Colorado
      • Denver, Colorado, United States, 80218
        • Rocky Mountain Cancer Center
    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • Washington Cancer Institute
      • Washington, District of Columbia, United States, 20007-2113
        • Georgetown University Medical Center-Lombardi Cancer Center
    • Florida
      • Melbourne, Florida, United States, 32901
        • Osler Medical Inc./Osler Clinical Research
      • Miami, Florida, United States, 33176
        • Advanced Medical Specialties
      • Orange Park, Florida, United States, 32073
        • Integrated Community
      • Orlando, Florida, United States, 32804
        • Florida Hospital Cancer Institute
      • Orlando, Florida, United States, 32806
        • MD Anderson Cancer Center
      • Pensacola, Florida, United States, 32501
        • Hematology Oncology Assoc.
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Emory University Cancer Institute
      • Augusta, Georgia, United States, 30912
        • Medical College of Georgia
    • Illinois
      • Chicago, Illinois, United States, 60612
        • University of Illinois at Chicago
      • Chicago, Illinois, United States, 60612
        • Rush University Medical Center
      • Chicago, Illinois, United States, 60637
        • University of Chicago Hospital
      • Chicago, Illinois, United States, 60612
        • Stroger Cook County Hospital
      • Maywood, Illinois, United States, 60153
        • Loyola University Medical Center
    • Indiana
      • Beech Grove, Indiana, United States, 46107
        • St. Francis Hospital & Health Centers
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa Hospitals & Clinics
    • Kansas
      • Wichita, Kansas, United States, 67214
        • Cancer Center of Kansas
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Louisville Oncology Research
    • Louisiana
      • Shreveport, Louisiana, United States, 71103
        • LSU Health Sciences Center
    • Maryland
      • Baltimore, Maryland, United States, 21229
        • St. Agnes Hospital
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan
      • Detroit, Michigan, United States, 48201
        • Wayne State University
      • Grosse Pointe, Michigan, United States, 48236
        • St. John Hospital and Medical Center
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic Hospital
    • Nebraska
      • Lincoln, Nebraska, United States, 68516
        • Southeast Nebraska Cancer Center
      • Omaha, Nebraska, United States, 68114
        • Nebraska Methodist Cancer Center
    • Nevada
      • Las Vegas, Nevada, United States, 89135
        • Nevada Cancer Institute
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
        • Hackensack University Medical Center
    • New Mexico
      • Albuquerque, New Mexico, United States, 87131
        • University of New Mexico Health Sciences Center
      • Santa Fe, New Mexico, United States, 87505
        • Cancer Institute of New Mexico
    • New York
      • Buffalo, New York, United States, 14263
        • Roswell Park Cancer Institute
      • Mineola, New York, United States, 11501
        • Winthrop Hematology/Oncology
      • New York, New York, United States, 10029
        • Mount Sinai Medical Center
      • New York, New York, United States, 10021
        • Weill Cornell Medical Center
      • New York, New York, United States, 10017
        • Memorial Sloan Kettering Cancer Center
      • Rochester, New York, United States, 14642
        • University of Rochester Medical Center
    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Duke University
      • Winston Salem, North Carolina, United States, 27157
        • Wake Forest University
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 734112
        • Cancer Care Associates
      • Tulsa, Oklahoma, United States, 74136
        • Cancer Care Associates
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health Sciences University
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15224
        • Western Pennsylvania Cancer Institute
    • South Carolina
      • Charleston, South Carolina, United States, 29403
        • Charleston Hematology Oncology
      • Charleston, South Carolina, United States, 29425
        • MUSC Hollings Cancer Center
      • Columbia, South Carolina, United States, 29203
        • Three Medical Park
      • Greenville, South Carolina, United States, 29615
        • Cancer Center Of The Carolinas
    • Tennessee
      • Germantown, Tennessee, United States, 38138
        • The Jones Clinic
      • Nashville, Tennessee, United States, 37232
        • Vanderbilt University Medical Center
    • Texas
      • Dallas, Texas, United States, 75390
        • UT Southwestern Medical Center
    • Utah
      • Salt Lake City, Utah, United States, 84106
        • Utah Cancer Specialists
    • Washington
      • Seattle, Washington, United States, 98104
        • Swedish Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  • Imatinib-resistant or -intolerant Philadelphia chromosome-positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase.
  • Chronic myeloid leukemia patients who have been treated with an investigational tyrosine kinase inhibitor.
  • Laboratory values within normal limits.

Exclusion criteria:

  • Impaired cardiac function.
  • Acute or chronic liver or renal disease considered unrelated to tumor.
  • Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.
  • Patients who are currently receiving treatment with any of the medications that have the potential to prolong the QT interval or to inhibit the metabolism of AMN107 (CYP3A4/5 inhibitors).
  • Patients with a history of another malignancy that is currently clinically significant or currently requires active intervention.

Other protocol-defined inclusion/exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Novartis Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2006

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2008

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 9, 2006

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 9, 2006

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 13, 2006

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 26, 2011

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 25, 2011

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CAMN107A2109

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings